




RealRate

PHARMACEUTICAL 2016

Aratana Therapeutics INC
Rank 166 of 295



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Aratana Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aratana Therapeutics INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 63% points. The greatest weakness of Aratana Therapeutics INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 62% points.

The company's Economic Capital Ratio, given in the ranking table, is 261%, being 2.6% points below the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	89,019
Cost of Goods Sold	0
Intangible Assets	54,848
Liabilities, Current	5,684
Liabilities, Non-Current	122
Other Assets	644
Other Compr. Net Income	-5,170
Other Expenses	43,693
Other Liabilities	39,710
Other Net Income	3,744
Other Revenues	678
Property and Equipment	2,555
Research and Development	24,964
Selling, General and Administrative Expense	19,819

Output Variable	Value in 1000 USD
Assets	147,066
Liabilities	45,516
Expenses	88,476
Revenues	678
Stockholders Equity	101,550
Net Income	-84,054
Comprehensive Net Income	-86,639
BaseVar	145,325
ECR before LimitedLiability	140%
Economic Capital Ratio	261%